Lazarte J, Lamango N
Biomedicines. 2024; 12(3.
PMID: 38540084
PMC: 10968070.
DOI: 10.3390/biomedicines12030470.
Soni U, Jenny L, Hegde R
J Exp Clin Cancer Res. 2023; 42(1):273.
PMID: 37858153
PMC: 10588251.
DOI: 10.1186/s13046-023-02850-7.
Monfort-Vengut A, de Carcer G
Pharmaceutics. 2023; 15(4).
PMID: 37111716
PMC: 10145883.
DOI: 10.3390/pharmaceutics15041232.
Ffrench B, Kashdan E, Huang Y, Spillane C, Cocchiglia S, Charmsaz S
Heliyon. 2023; 9(1):e13044.
PMID: 36747925
PMC: 9898658.
DOI: 10.1016/j.heliyon.2023.e13044.
Downes C, McClure B, McDougal D, Heatley S, Bruning J, Thomas D
Front Cell Dev Biol. 2022; 10:942053.
PMID: 35903543
PMC: 9315936.
DOI: 10.3389/fcell.2022.942053.
Molecular docking analysis of HER-2 inhibitor from the ZINC database as anticancer agents.
Sait K, Mashraqi M, Khogeer A, Alzahrani O, Anfinan N, Sait H
Bioinformation. 2021; 16(11):882-887.
PMID: 34803263
PMC: 8573456.
DOI: 10.6026/97320630016882.
Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets.
Khorsandi S, Dokal A, Rajeeve V, Britton D, Illingworth M, Heaton N
Cancer Res. 2021; 81(22):5765-5776.
PMID: 34551960
PMC: 9397618.
DOI: 10.1158/0008-5472.CAN-21-0955.
Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction.
Ito R, Oneyama C, Aoki K
PLoS One. 2021; 16(4):e0249388.
PMID: 33793658
PMC: 8016361.
DOI: 10.1371/journal.pone.0249388.
Regulation of efferocytosis as a novel cancer therapy.
Zhou Y, Yao Y, Deng Y, Shao A
Cell Commun Signal. 2020; 18(1):71.
PMID: 32370748
PMC: 7199874.
DOI: 10.1186/s12964-020-00542-9.
Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study.
Byeon S, Hong J, Lee J, Nam D, Park S, Park J
Target Oncol. 2020; 15(2):185-192.
PMID: 32107712
DOI: 10.1007/s11523-020-00706-0.
Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?.
Espay A, Kalia L, Gan-Or Z, Williams-Gray C, Bedard P, Rowe S
Neurology. 2020; 94(11):481-494.
PMID: 32102975
PMC: 7220234.
DOI: 10.1212/WNL.0000000000009107.
Molecular Analysis of Liquid-Based Cytological Specimen Using Virtually Positive Sputum with Adenocarcinoma Cells.
Nishikawa T, Fujii T, Tatsumi S, Sugimoto A, Sekita-Hatakeyama Y, Shimada K
Diagnostics (Basel). 2020; 10(2).
PMID: 32033355
PMC: 7168204.
DOI: 10.3390/diagnostics10020084.
Genetic links between endometriosis and cancers in women.
Bhyan S, Zhao L, Wee Y, Liu Y, Zhao M
PeerJ. 2019; 7:e8135.
PMID: 31879572
PMC: 6927350.
DOI: 10.7717/peerj.8135.
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
Zhu C, Wei Y, Wei X
Mol Cancer. 2019; 18(1):153.
PMID: 31684958
PMC: 6827209.
DOI: 10.1186/s12943-019-1090-3.
Targeting c-met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma.
Zhang Y, Gao H, Zhou W, Sun S, Zeng Y, Zhang H
J Cell Mol Med. 2018; 22(12):5978-5990.
PMID: 30353654
PMC: 6237600.
DOI: 10.1111/jcmm.13870.
The Src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases.
Shah N, Amacher J, Nocka L, Kuriyan J
Crit Rev Biochem Mol Biol. 2018; 53(5):535-563.
PMID: 30183386
PMC: 6328253.
DOI: 10.1080/10409238.2018.1495173.
Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients.
Wang C, Chen F, Liu Y, Xu Q, Guo L, Zhang X
Front Pharmacol. 2018; 9:360.
PMID: 29695969
PMC: 5904969.
DOI: 10.3389/fphar.2018.00360.
Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK.
Buhrmann M, Wiedemann B, Muller M, Hardick J, Ecke M, Rauh D
PLoS One. 2017; 12(9):e0184627.
PMID: 28892510
PMC: 5593189.
DOI: 10.1371/journal.pone.0184627.
Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
Simon M, Mesmar F, Helguero L, Williams C
PLoS One. 2017; 12(2):e0172832.
PMID: 28235006
PMC: 5325553.
DOI: 10.1371/journal.pone.0172832.
Safe dose of intravitreal imatinib and its effect on laser-induced choroidal neovascularization: a rat-model experiment.
Nikkhah H, Ahmadieh H, Ramezani A, Kanavi M, Hosseini S, Sadeghi N
Int J Retina Vitreous. 2016; 1:16.
PMID: 27847609
PMC: 5088484.
DOI: 10.1186/s40942-015-0017-4.
